Vectorite Biomedical Documents
Documents
0
Ticker
4170.TWO
ISIN
TW0004170006
Vectorite Biomedical SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Vectorite Biomedical Documents 2026
This page contains all official documents and SEC filings for Vectorite Biomedical stock (4170.TWO, ISIN: TW0004170006). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Vectorite Biomedical's regulatory filings.
Vectorite Biomedical Stock analysis
Vectorite Biomedical Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically.